Sugi Predict

Sugi Predict / Compounds / SCHEMBL1753885

SCHEMBL1753885

SCHEMBL1753885

CC(=O)Nc1ccc(F)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.81
▸ MEN1 O00255 5/20 0.81
▸ POLB P06746 2/20 0.81
▸ SMN1; SMN2 Q16637 4/20 0.67
▸ HTT P42858 1/20 0.67
▸ L3MBTL1 Q9Y468 1/20 0.67
▸ LMNA P02545 1/20 0.66
▸ GAA P10253 1/20 0.66
▸ ALDH1A1 P00352 3/20 0.64
▸ MAPT P10636 2/20 0.64
▸ TDP1 Q9NUW8 1/20 0.64
▸ CA12 O43570 1/20 0.64
▸ BRD4 O60885 1/20 0.64
▸ NR1I2 O75469 1/20 0.64
▸ CA1 P00915 1/20 0.64
▸ CA2 P00918 1/20 0.64
▸ MB P02144 1/20 0.64
▸ CYP1A1 P04798 1/20 0.64
▸ CA3 P07451 1/20 0.64
▸ CYP3A4 P08684 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2615418 1.00 KMT2A (0.81) KMT2AMEN1POLBSMN1; SMN2HTT
Hydrochloric Acid SCHEMBL30443411 0.98 KMT2A (0.78) KMT2AMEN1POLBSMN1; SMN2HTT
SCHEMBL24878628 0.94 SMN1; SMN2 (0.79) KMT2AMEN1POLBSMN1; SMN2HTT
SCHEMBL4455279 0.94 KMT2A (0.72) KMT2AMEN1POLBSMN1; SMN2HTT
SCHEMBL10924278 0.88 KMT2A (0.68) KMT2AMEN1POLBSMN1; SMN2HTT
SCHEMBL14384682 0.88 KMT2A (0.66) KMT2AMEN1POLBSMN1; SMN2HTT
SCHEMBL861674 0.87 SMN1; SMN2 (0.84) KMT2AMEN1POLBSMN1; SMN2HTT
SCHEMBL3673286 0.87 PKM (0.72) KMT2AMEN1POLBLMNAGAA
SCHEMBL27995160 0.85 KMT2A (0.62) KMT2AMEN1POLBSMN1; SMN2HTT
SCHEMBL28155923 0.84 KMT2A (0.60) KMT2AMEN1POLBSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4578447-A1 ERCC1-XPF COMPLEX INHIBITOR COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud (PT) 2025-07-02 — — EP claimed
CN-120040437-A Novel heterocyclic compound and pharmaceutical composition comprising same 株式会社大熊制药 2025-05-27 — — CN claimed
WO-2025074340-A1 A PROCESS FOR PREPARATION OF AMINOBIPHENYL COMPOUNDS AND INTERMEDIATES THEREOF UPL LIMITED (IN) 2025-04-10 — — WO claimed
CN-119431706-A Fatigue-resistant polyurethane elastomer and preparation method and application thereof 万勋科技(深圳)有限公司 2025-02-14 — — CN claimed
WO-2024131893-A1 IRE1α SMALL MOLECULE INHIBITORS SHANGHAI YI ZHONG XING BIOTECHNOLOGY CO., LTD. (CN) 2024-06-27 — — WO claimed
CN-112110824-B Method for preparing 2-bromo-5-fluoroaniline 上海凌凯医药科技有限公司 2023-04-07 — — CN claimed
CN-115636798-A Preparation method and application of substituted triaminotriazine compound 中国人民解放军海军军医大学 2023-01-24 — — CN claimed
US-20220274926-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES INC (US) 2022-09-01 — — US claimed
CN-113416139-B 4-fluorine substituted aryl amine compound and synthetic method thereof 江苏笃行致远新材料科技有限公司 2022-06-03 — — CN claimed
CN-113999130-A Preparation method of o-nitroanilide compound 湖北工业大学 2022-02-01 — — CN claimed
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives PHARMACIA & UPJOHN COMPANY 2003-12-04 — — US claimed
US-20030220321-A1 Substituted azepino[4,5b]indole derivatives PHARMACIA & UPJOHN COMPANY 2003-11-27 — — US claimed
US-6586421-B2 For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders PHARMACIA & UPJOHN COMPANY 2003-07-01 — — US claimed
EP-1319004-A2 SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2003-06-18 — — EP claimed
EP-1319005-A2 SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2003-06-18 — — EP claimed
US-20020107278-A1 Substituted azepino[4,5b]indole derivatives PHARMACIA & UPJOHN COMPANY 2002-08-08 — — US claimed
CN-1353609-A Amide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES CO (US) 2002-06-12 — — CN claimed
WO-2002024701-A2 SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2002-03-28 — — WO claimed
WO-2002024700-A2 SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2002-03-28 — — WO claimed
CN-1079219-A Arylacetamide MERCK PATENT GMBH (DE) 1993-12-08 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107278-A1 Substituted azepino[4,5b]indole derivatives HTR5A, HTR1A, HTR1E KMT2A 2844/4885MEN1 852/4885POLB 4371/4885
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives HTR5A, HTR1A, HTR4 KMT2A 2421/4885MEN1 959/4885POLB 4160/4885
US-20220274926-A1 IMMUNOREGULATORY AGENTS IDO1, IDO2, INMT KMT2A 1557/4885MEN1 3659/4885POLB 3533/4885
US-20030220321-A1 Substituted azepino[4,5b]indole derivatives HTR5A, HTR1A, HTR1E KMT2A 2844/4885MEN1 852/4885POLB 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.